In an era where personalized, advanced health care is increasingly critical, the autologous stem cell and non-stem cell-based therapies market is an essential area of focus. With tremendous transformative potential, these therapies have ushered in a new approach, leveraging one's own cells to heal and regenerate tissue.
In the swiftly shifting healthcare landscape, understanding the trend line for autologous stem cell and non-stem cell-based therapies is crucial for savvy business executives. The market trends are largely shaped by the rising prevalence of targeted diseases, novel introductions in regenerative medicine, and an increase in the global geriatric population, a demographic often facing degenerative diseases. Securing a comprehensive market report will provide an in-depth study of the current market scenario, future predictions, and the competitiveness of this booming sector. Keep ahead of the change and make truly informed decision-making with this essential market report.
The COVID-19 pandemic affected the healthcare industry, especially the surgery and therapy sectors. Several treatments and surgeries that were deemed non-urgent were either canceled or postponed, which significantly affected the market’s growth during the initial phase of the pandemic. However, with the growing complications associated with COVID-19 patients, the demand for stem cell-based therapies increased to a great extent. For instance, as per a study by a group of researchers from Poland published in the journal Medicina in July 2021, hematologic stem cell transplantation recipients were at a higher risk of COVID-19-associated complications due to underlying disease, the immunosuppressive effect of conditioning, and delayed immune reconstitution. The uncontrolled production of neutrophil extracellular traps and cytokines in patients affected by COVID-19 correlated with disease severity and lung injury extension. Such studies highlighted the need for appropriate treatment considering autologous stem cell and non-stem cell-based therapies, thereby driving the market’s growth during the post-pandemic period.
Factors driving the market’s growth are the rising prevalence of targeted diseases, the introduction of novel autologous stem cell-based therapies in regenerative medicine, and the increase in the geriatric population.
There is a significant increase in the geriatric population around the world. For instance, the number of people over the age of 85 in the United Kingdom is projected to reach 3.1 million by mid-2045, as stated by the United Kingdom Office for National Statistics in January 2022. According to the data published by the Indian Ministry of Statistics and Programme Implementation in July 2021, the population over the age of 60 in India is expected to increase from 138 million in 2021 to around 194 million by 2031. As people age, there is an increase in the occurrence of degenerative diseases, which could be treated with the help of stem cell therapy. The growing older population is expected to increase the demand for innovative disease treatment procedures, thereby accelerating the growth of the global autologous stem cell and non-stem cell-based therapies market.
Stem cell technology is a speedily developing technology that plays a major role in regenerative medicine. It also serves the disciplines of tissue engineering, developmental cell biology, cellular therapeutics, gene therapy, chemical biology, and nanotechnology. Stem cells can replace the cells and tissues to treat various conditions, including spinal cord injury, arthritis, and Parkinson’s disease. According to the CDC, in October 2021, around 63 million people in the United States were estimated to have been affected by arthritis, with the numbers estimated to rise to 78 million by 2040. There has been an increase in research on using stem cells as experimental treatments for arthritis to help regrow cartilage. The applications of stem cell technologies in such treatments increased the overall adoption rate of these technologies across the world. The advantage of an autologous stem cell transplant is that one gets one’s cells back, and there is no risk of rejection from the immune system of the individual. Such research studies are expected to contribute to the growth of the market studied over the forecast period.
The product approvals concerning autologous stem cell-based therapies are expected to boost the growth of the market. For instance, in March 2021, the US FDA approved Novadip’s Investigational New Drug (IND) application for its autologous cell therapy product NVD‑003 for treating congenital pseudarthrosis of the tibia.
The aforementioned factors are expected to boost the growth of the market studied during the forecast period. However, the high cost of autologous cellular therapies and the lack of skilled professionals are anticipated to hinder the market’s growth.
Autologous Stem Cell & Non Stem Cell Based Therapies Market Trends
Cancer Segment Holds Significant Share in the Autologous Stem Cell and Non-Stem Cell Based Therapies MarketCancer is a leading cause of death all around the world. According to the Cancer Facts & Figures published by the CDC, an estimated 1.9 million new cancer cases will be diagnosed, and 609,360 cancer deaths will occur in the United States in 2022. By 2030, the global burden is expected to grow to 21.7 million new cancer cases. It is expected to reach 28.4 million cases in 2040, a 47% rise from 2020, according to an article published in the American Cancer Society journal in 2021. Appropriate treatments with the use of patient stem cells and public health action by governments and health practitioners may prevent as many as one-third of cancers worldwide.
The large population affected by cancer in developing countries is expected to have a major impact on the growth of the studied market. The NCI reports that more than 60% of the world’s new cancer cases occur in Africa, Asia, and Central and South America; 70% of cancer deaths also occur in these regions. According to the IARC, by 2030, the global burden of cancer is expected to rise to 21.7 million new cases and 13 million cancer deaths due to the growth and aging of the population, leaving aside factors such as smoking, poor diet, physical inactivity, and fewer childbirths in economically developing countries. According to the WHO, 70% of deaths from cancer occur in low- and middle-income countries, and only one in five low- and middle-income countries has the necessary data to drive cancer policy. This global and extensive threat of cancer remains a major market driver for new cancer therapies that help in risk assessment, early diagnosis, and effective monitoring of treatment. The extensive spread of the disease across the world is expected to boost the segment's growth during the forecast period.
Several key market players have been contributing to the growth of the segment. For instance, in June 2021, Kite, a Gilead Company, announced top-line results from the primary analysis of ZUMA-7, a randomized Phase 3 global, multicenter study showing the superiority of Yescarta (axicabtagene ciloleucel), a CD19-directed genetically modified autologous T cell immunotherapy, compared to the standard of care in second-line relapsed or refractory large B-cell lymphoma.
Such activities are expected to promote the growth of the autologous stem cell and non-stem cell-based therapies market during the forecast period.
North America Dominates the Autologous Stem Cell and Non-Stem Cell Based Therapies MarketNorth America dominated the autologous stem cell and non-stem cell-based therapies market, with the United States contributing the largest share of the market.
The rising number of chronic disease cases in North America is contributing to the growth of the market. As per the data published by the Canadian Cancer Society, in 2022, approximately 30,000 Canadians were estimated to be diagnosed with lung cancer. This represents 13% of all new cancer cases in the country, indicating a large potential market demand for stem cell therapies.
Around 37.3 million people in the United States were found to have diabetes, and around 96 million adults were found to have pre-diabetes, as per CDC data published in January 2022. According to the National Kidney Foundation, in 2021, 36 million adults in the United States were estimated to have chronic kidney disease. Around 15.7 million Americans are affected by chronic lower respiratory diseases. Owing to their high proliferation and differentiation capacities, paracrine activity, and immunologic privilege, autologous stem cell therapies are considered for the clinical treatment of various chronic diseases. The large population affected by chronic diseases and the increase in the necessity of autologous stem cell and non-stem cell-based therapy for the efficient treatment of such diseases are expected to propel the growth of the market in the region.
The recent programs for the development of novel technologies based on autologous stem cell therapies are expected to drive the market's growth in the region. For instance, in March 2021, Health Canada held a workshop on the regulation of autologous stem cell-based therapies prepared by physicians at the point of care for use in orthopedic applications, including for osteoarthritis and pain. The workshop helped address misconceptions about autologous stem cell-based products and identified potential barriers to providing access to patients in Canada. Researchers hoped that the transplanted stem cells might develop into new neurons that could replace lost nerve connections and restore at least some motor and sensory functions.
Thus, the market studied is anticipated to grow in North America due to the aforementioned factors.
Autologous Stem Cell & Non Stem Cell Based Therapies Market Competitor AnalysisThe global autologous stem cell and non-stem cell-based therapies market is competitive, fragmented, and consists of a few major players. The companies, which include Novartis AG, BrainStorm Cell Limited, Caladrius, Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC, Gilead Sciences Inc., Regeneus Ltd, and US Stem Cell Inc., among others, hold a substantial share in the growth of the market studied.
Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Rising Prevalence of Targeted Diseases
4.2.2 Introduction of Novel Autologous Stem Cell Based Therapies in Regenerative Medicine
4.2.3 Increasing Geriatric Population
4.3 Market Restraints
4.3.1 High Cost of Autologous Cellular Therapies
4.3.2 Lack of Skilled Professionals
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Autologous Stem Cells
5.1.2 Autologous Non-Stem cells
5.2 By Application
5.2.2 Neurodegenerative Disorders
5.2.3 Cardiovascular Disease
5.2.4 Orthopedic Diseases
5.2.5 Other Applications
5.3 By End User
5.3.2 Ambulatory Surgical Centers
5.3.3 Research Facilities
5.4.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.4.4 Middle East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle East and Africa
5.4.5 South America
220.127.116.11 Rest of South America
6.1.1 Novartis International AG
6.1.2 BrainStorm Cell Limited
6.1.3 Caladrius Biosciences Inc.
6.1.4 Cytori Therapeutics Inc.
6.1.5 Dendreon Pharmaceuticals LLC
6.1.6 Castle Creek Biosciences Inc.
6.1.7 Holostem Terapie Avanzate Srl
6.1.8 Vericel Corp.
6.1.9 US Stem Cell Inc.
6.1.10 Gilead Sciences Inc.
A selection of companies mentioned in this report includes:
- Novartis International AG
- BrainStorm Cell Limited
- Caladrius Biosciences Inc.
- Cytori Therapeutics Inc.
- Dendreon Pharmaceuticals LLC
- Castle Creek Biosciences Inc.
- Holostem Terapie Avanzate Srl
- Vericel Corp.
- US Stem Cell Inc.
- Gilead Sciences Inc.